

# UMR Medical Policy Update Bulletin *Quick View:* December 2024



A list of recently approved, revised, and/or retired Medical Policies and/or Medical Benefit Drug Policies is provided below for your reference. **For a comprehensive summary of the latest updates, refer to the [Medical Policy Update Bulletin: December 2024](#).**

## Take Note

### Annual CPT and HCPCS Code Updates

Beginning **Jan. 1, 2025**, all applicable Medical Policies and Medical Benefit Drug Policies will be updated to reflect the 2025 Current Procedural Terminology (CPT<sup>®</sup>) and Healthcare Common Procedure Coding System (HCPCS) code additions, revisions, and deletions. Refer to the following sources for information on the code updates:

- [American Medical Association: Current Procedural Terminology: CPT<sup>®</sup>](#)
- [Centers for Medicare & Medicaid Services: Healthcare Common Procedure Coding System \(HCPCS\) Quarterly Update](#)

Complete details on impacted policies and corresponding code edits will be provided in the January 2025 edition of the Medical Policy Update Bulletin.

## Medical Benefit Drug Policy Updates

Policy Title	Status	Effective Date
Antiemetics for Oncology	Revised	Jan. 1, 2025
Ilumya <sup>®</sup> (Tildrakizumab-Asmn)	Revised	Jan. 1, 2025
Immune Globulin (IVIG and SCIG)	Revised	Jan. 1, 2025
Infliximab (Avsola <sup>®</sup> , Inflectra <sup>®</sup> , Remicade <sup>®</sup> , & Renflexis <sup>®</sup> )	Revised	Jan. 1, 2025
Kisunla <sup>™</sup> (Donanemab-Azbt)	Updated	Jan. 1, 2025
Leqvio <sup>®</sup> (Inclisiran)	Revised	Jan. 1, 2025
Long-Acting Injectable Antiretroviral Agents for HIV	Revised	Jan. 1, 2025
Maximum Dosage and Frequency	Revised	Jan. 1, 2025
Ocrevus <sup>®</sup> (Ocrelizumab) and Ocrevus Zunovo <sup>™</sup> (Ocrelizumab and Hyaluronidase-Ocsq)	Revised	Jan. 1, 2025
Omvoh <sup>®</sup> (Mirikizumab-Mrkz)	Revised	Jan. 1, 2025
Oncology Medication Clinical Coverage	Revised	Jan. 1, 2025
Ophthalmologic Policy: Vascular Endothelial Growth Factor (VEGF) Inhibitors	Updated	Jan. 1, 2025
Provider Administered Drugs – Site of Care	Revised	Jan. 1, 2025
Rebyota <sup>®</sup> (Fecal Microbiota, Live-Jslm)	Updated	Jan. 1, 2025
Respiratory Interleukins (Cinqair <sup>®</sup> , Fasentra <sup>®</sup> , & Nucala <sup>®</sup> )	Revised	Jan. 1, 2025
Rituximab (Riabni <sup>®</sup> , Rituxan <sup>®</sup> , Ruxience <sup>®</sup> , & Truxima <sup>®</sup> )	Revised	Jan. 1, 2025
Tremfya <sup>®</sup> (Guselkumab)	New	Jan. 1, 2025
Xiaflex <sup>®</sup> (Collagenase Clostridium Histolyticum)	Revised	Jan. 1, 2025

## General Information

The inclusion of a health service (e.g., test, drug, device, or procedure) in this bulletin indicates only that UnitedHealthcare is adopting a new policy and/or updated, revised, replaced, or retired an existing policy; it does not imply that UnitedHealthcare provides coverage for the health service. Note that most benefit plan documents exclude from benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health care professionals may not seek or collect payment from a member for services not covered by the applicable benefit plan unless first obtaining the member's written consent, acknowledging that the service is not covered by the benefit plan and that they will be billed directly for the service.

**Note:** The absence of a policy does not automatically indicate or imply coverage. As always, coverage for a health service must be determined in accordance with the member's benefit plan and any applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence supporting the safety and effectiveness of a medical technology prior to rendering a coverage determination.

UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Medical Policy Update Bulletin was developed to share important information regarding changes to our Medical Policies and Medical Benefit Drug Policies. When information in this bulletin conflicts with applicable state and/or federal law, UnitedHealthcare follows such applicable federal and/or state law.

UMR is a wholly owned subsidiary of UnitedHealthcare, a part of UnitedHealth Group. UMR is a third-party administrator (TPA) for self-funded plans.

## Policy Update Classifications

### *New*

New clinical coverage criteria have been adopted for a health service (e.g., test, drug, device, or procedure)

### *Updated*

An existing policy has been reviewed and changes have not been made to the clinical coverage criteria; however, items such as the clinical evidence, FDA information, and/or list(s) of applicable codes may have been updated

### *Revised*

An existing policy has been reviewed and revisions have been made to the clinical coverage criteria

### *Replaced*

An existing policy has been replaced with a new or different policy

### *Retired*

The health service(s) addressed in the policy are no longer being managed or are considered to be proven/medically necessary and are therefore not excluded as unproven/not medically necessary services, unless coverage guidelines or criteria are otherwise documented in another policy



The complete library of UMR Medical Policies and Medical Benefit Drug Policies is available at [UHCprovider.com/policies](https://UHCprovider.com/policies) > For Commercial Plans > [UnitedHealthcare | UMR Medical & Drug Policies](#).